Biogen (BIIB) Stock Price, News & Analysis

Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $148.23 to $151.88
• 50-Day Range: $146.47 to $185.90
• 52-Week Range: $145.07 to $268.30
• Volume: 1.13 million shs
• Average Volume: 1.21 million shs
• Market Capitalization: $22.05 billion
• P/E Ratio: 13.67
• Dividend Yield: N/A
• Price Target: $242.68
• Consensus Rating: Hold

Biogen Stock Analysis - MarketRank™

Biogen scored higher than 98% of companies evaluated by MarketBeat, and ranked 29th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Biogen has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 13 buy ratings, 16 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biogen has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 2.50%

Earnings Growth

Earnings for Biogen are expected to grow by 2.50% in the coming year, from $16.43 to $16.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biogen is 13.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biogen is 13.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.23.

Price to Earnings Growth Ratio

Biogen has a PEG Ratio of 1.83. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Biogen has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.78% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biogen has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biogen does not currently pay a dividend.

Dividend Growth

Biogen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.95

Percentage of Shares Shorted

1.78% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biogen has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.70

News Sentiment

Biogen has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Biogen this week, compared to 20 articles on an average week.

Search Interest

Only 30 people have searched for BIIB on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.

MarketBeat Follows

18 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.16% of the stock of Biogen is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BIIB Stock Analysis - Frequently Asked Questions

How have BIIB shares performed this year?

Biogen's stock was trading at $258.77 at the beginning of 2024. Since then, BIIB shares have decreased by 41.5% and is now trading at $151.31.
View the best growth stocks for 2024 here.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $4.08 earnings per share for the quarter, topping analysts' consensus estimates of $3.77 by $0.31. The business's revenue was down 2.5% compared to the same quarter last year.
Read the conference call transcript.

Does Biogen have any subsidiaries?

Biogen subsidiaries include these companies: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and others.

Who are Biogen's major shareholders?

Top institutional investors of Biogen include Primecap Management Co. CA (11.20%), State Street Corp (5.04%), Wellington Management Group LLP (3.52%) and Geode Capital Management LLC (2.48%). Insiders that own company stock include Susan H Alexander, Eric K Rowinsky, Ginger Gregory and Priya Singhal.
View institutional ownership trends.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC).

Company Calendar

• Last Earnings: 10/30/2024
• Today: 12/28/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIIB
• CUSIP: 09062X10
• CIK: 875045
• Web: www.biogen.com
• Phone: (617) 679-2000
• Fax: 617-679-2617
• Employees: 7,570
• Year Founded: 1978

Price Target and Rating

• Average Stock Price Target: $242.68
• High Stock Price Target: $342.00
• Low Stock Price Target: $164.00
• Potential Upside/Downside: +60.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.45
• Research Coverage: 29 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $11.07
• Trailing P/E Ratio: 13.67
• Forward P/E Ratio: 9.21
• P/E Growth: 1.83
• Net Income: $1.16 billion
• Net Margins: 16.81%
• Pretax Margin: 19.84%
• Return on Equity: 14.98%
• Return on Assets: 8.59%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 1.26
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: $9.61 billion
• Price / Sales: 2.29
• Cash Flow: $17.72 per share
• Price / Cash Flow: 8.54
• Book Value: $102.14 per share
• Price / Book: 1.48

Miscellaneous

• Outstanding Shares: 145,719,000
• Free Float: 145,486,000
• Market Cap: $22.05 billion
• Optionable: Optionable
• Beta: -0.08